TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an update.
Paradigm Biopharmaceuticals Ltd has released its corporate governance statement for the financial year ending June 30, 2025, which is accessible on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability in management and oversight. This announcement reinforces Paradigm’s dedication to maintaining robust governance practices, which may positively impact stakeholder confidence and the company’s market positioning.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company is primarily engaged in creating treatments for various medical conditions, aiming to improve patient outcomes and address unmet medical needs.
Average Trading Volume: 802,643
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$115M
Learn more about PAR stock on TipRanks’ Stock Analysis page.